BAL 30072

Drug Profile

BAL 30072

Alternative Names: BAL0030072; BAL30072

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Class Antibacterials; Monobactams; Pyridones
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gram-negative infections

Highest Development Phases

  • Phase I Gram-negative infections
  • Discontinued Respiratory tract infections

Most Recent Events

  • 15 Aug 2016 BAL 30072 is still in phase I trials for Gram-negative-infections (In volunteers) in Switzerland (IV, Infusion)
  • 15 Aug 2016 Discontinued for Respiratory tract infections in Switzerland (Inhalation)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Switzerland (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top